PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “MENIERE'S DISEASE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 865 records · Page 48Linked to original sources

Intratympanic gentamicin for the treatment of Meniere's disease and other forms of peripheral vertigo.

Titration therapy with intratympanic gentamicin offers class A or B control of vertigo in 87% (range, 75%-100%) of patients with unilateral Ménière's disease. The risk of additional hearing loss is about 21% (range,0-37%). Vertigo may recur, however, in nearly one third of patients over time. These recurrences can also be treated by intratympanic gentamicin with a similar risk of hearing loss. The salient effect of intratympanic gentamicin is probably the reduction of vestibular function through damage to hair cells, but a complete ablation of function does not seem to be necessary for vertigo control.

Administration, Topical↗

Longterm results of ultrasonic irradiation in Meniere's disease.

Thirty-seven patients with Ménière's disease were treated with ultrasonic irradiation to the lateral and superior semicircular canals. In a longterm follow-up study, lasting alleviation of the vertiginous attacks was found in 24 out of 33 patients (72%). In most of the cases, hearing remained unchanged. It is suggested that the therapeutic effect is associated with a change in the endolymphatic drainage dur to histological alterations in the labyrinth produced by ultrasound.

Adult↗

[Meniere's disease: diagnosis and new treatment perspectives].

Ménière's disease is characterized by attacks of vertigo and by sensorineural hearing loss, tinnitus, and ear fullness; these cochlear symptoms are unilateral in the majority of cases. Medical treatment tends to control vertigo and to cure the possible causes of endolymphatic hydrops (autoimmune disease, syphilis, metabolic and endocrine derangements, etc). In case of failure of medical treatment, surgery is considered. Endolymphatic mastoid shunt is indicated when hearing is normal or fluctuating. In all other cases, vestibular neurectomy or chemical vestibular labyrinthectomy, by means of intratympanic low concentration gentamicin (20 mg/mL), are indicated. Total or substantial regression of vertigo, at 2 years follow up, occurs in 65% of cases after endolymphatic-mastoid shunt, and in > 90% after vestibular neurectomy or chemical vestibular labyrinthectomy.

Diagnosis, Differential↗

Pathology and pathophysiology of Meniere's disease.

Histopathologic study of the human temporal bone entails microscopic examination and analysis of a series of histologic sections. This is currently the most effective method for observing the pathologic conditions of MD by examining the entire inner ear. Complete temporal bone histopathology cannot be replaced by either clinical pathologic study of small biopsy specimens obtained during surgery, or experimental animal studies that can create endolymphatic hydrops but not create MD. We believe that the histopathologic findings together with clinical information on MD is valuable in enhancing our understanding of the pathophysiology of the inner ear in MD. For example, a hypoplastic VA and ES in MD seem to indicate that there may be congenital predisposing factors in the development of MD. The exact pathologic findings characteristic of MD remains unclear, however. Many of the temporal bone specimens were obtained years after patients were diagnosed with MD and those specimens were involved with moderate postmortem changes. For these reasons, further collection of temporal bone specimens with fewer postmortem changes, obtained within a shorter premortem time period between occurrence of the disease and the time of the patients' death, and from patients with a well-characterized clinical history of MD, is imperative. Contemporary temporal bone studies now include in situ hybridization histochemistry or polymerase chain reaction (PCR) analysis for protein, enzymes, or viral antigens that can be directed at specimens from patients with MD [54,55]. It is hoped that in the near future such advanced research studies with human temporal bone histology sections will support and enhance the significant contribution of temporal bone histopathology to clinical otology.

Autopsy↗

Meniere's disease: the selection and assessment of patients for surgery using electrocochleography.

Transtympanic electrocochleography has been used to measure the action potential (AP), summating potential (SP), and cochlear microphonic (CM) in patients with Menière's disease. In this condition the widening of the AP/SP complex is thought to be due to an enhanced negative SP which shows no adaptation and this may be the result of an increased asymmetry produced by endolymphatic hydrops. Measurements have also been made using two groups of agents -- those designed to increase the cochlear blood flow (the metabolic activator naftidrofuryl and inhalations of carbon dioxide) and those designed to reduce the hydrops "osmotically" (glycerol) or by diuresis. It was hoped that the "glycerol dehydration test" when assessed electrocochleographically would lead to a better selection of patients for surgical decompression of the saccus endolymphaticus. It was also hoped that it would lead to a fuller understanding of the electrophysiological changes which occur in Menière's disease. While it appeared that a decrease in the negative SP after glycerol may be a more sensitive indicator of the changes within the cochlea than either pure-tone audiometry or speech discrimination, no clearcut correlations between this change and the surgical result could be demonstrated. In many patients the AP/SP waveform remained unchanged after successful surgery, indicating perhaps that the pathological changes may have been checked but not reversed, while the hearing remained "pegged" at its preoperative level. Electrocochleography during operation failed to show any consistent change in the waveform or CM.

Acoustic Stimulation↗

Meniere's disease and the summating potential. II. Vestibular test results.

Results of electronystagmographic (ENG) position and bithermal caloric tests from patients with abnormally enlarged summating potentials (SPs) were compared with results from a unilateral weakness (UW)-matched ENG-comparison group and with a group of patients with unilateral cochlear deficits and dizziness but without enlarged SPs. The patients with enlarged SPs had significantly higher incidence of caloric UW on the involved side than did the patients with cochlear deficits but without enlarged SPs. Also, the patients with SP enlargement had a significantly higher incidence of directional preponderance toward the involved side than did either of the comparison groups. Across-group differences in position test results were predictable from the caloric test results, but these differences were not statistically significant.

Adult↗

Ultrasound treatment of Meniere's disease. Long-term follow-up of 356 advanced cases.

Twelve years' experience of ultrasound treatment of 356 patients is presented. For evaluating the results a new multifacetted scoring system was developed, where each individual patient was evaluated on the basis of four parameters. According to this evaluation 71% of the patients improved after the operation, while 29% remained unchanged or deteriorated. Because of lack of improvement, 42 patients underwent reoperation by different methods; in half of them ultrasonic irradiation was again used. The hearing deteriorated in about 40% of the patients, to which result the long observation times also contributed. The caloric response became reduced in 70% of the patients. Marked depression of the caloric response characterized the patients who were relieved of vertigo. Transient facial paralysis in 4 patients was the only complication.

Adult↗

[Vestibular neurectomy by retrolabyrinthine approach in cases of untreatable Meniere's disease].

We report on a series of 35 Ménière's disease patients, all of whom had undergone retrolabyrinthine vestibular neurectomy between 1987-1993. The overall success rate of vertigo relief was 96.7% with no serious or permanent complications resulting from the procedure. The current literature is reviewed and our results are compared with those of previous reports. The technical elements of the operation, regarding our approach and those of the others are analyzed with special attention given to the anatomical features of the region and their influence on success or failure. We conclude that the retrolabyrinthine approach for nerve section remains a safe and highly successful technique which continues to be widely used.

Adult↗

Histopathology of cryosurgery for Meniere's disease.

The histopathologic findings in the temporal bones of two patients who underwent a cryo-otic-perotic shunt procedure are reported. Morphologic changes in the inner ear were limited to the area of cryoprobe application on the promontory. The hook region of the cochlear duct showed severe atrophy of the spiral ligament, stria vascularis, and sensorineural structures. The ampulla of the posterior semicircular canal showed fibrosis in the perilymphatic space and ruptured membranous walls. No changes were found in the rest of the vestibular labyrinth or in the facial nerve. The long-term improvement in these patients' symptoms, i.e., eight years in one and four years in the other, could only be explained on the basis that endolymph and perilymph mix across intact, nonfunctioning membranes of the cochlear duct or through, presumably antemortem, ruptures of the posterior semicircular canal ampulla.

Aged↗

[Evoked otoacoustic emission in conduction of dehydration tests in patients with Meniere's disease].

We studied potentiality of the test of evoked otoacoustic emission (EOAE) for monitoring of dynamic changes in the internal ear in conduction of dehydration tests. In parallel to registration of tonal hearing thresholds and speech intelligibility in conduction of dehydration tests we registered two classes of EOAE: delayed EOAE (DEOAE) and distortion product otoacoustic emission (DPOAE). Of 36 examinees, we registered DEOAE prior to dehydration in 22 patients. By audiometry, these patients had hearing under 40 dB lower the hearing threshold at frequencies 250-4000 Hz. In registration of DEOAE in dynamics a maximal amplitude increase was seen 2 hours after intake of glycerin. A mean amplitude increase was 7.0+/-2.3 dB. Before dehydration DEOAE was recorded in 26 of 36 patients. Two hours laser otoacoustic response was registered in 29 patients. Hearing loss was not more than 60 dB at frequencies 250-4000 Hz. A maximal amplitude increase was seen in 2 hours. A mean amplitude increase in dehydration was 7.3+/-3.7 dB.

Adult↗

A case of Meniere's disease with vertical nystagmus after administration of glycerol.

A 62-year-old woman who complained of repetitive vertigo with a left fluctuating hearing loss was admitted to our hospital three times. A glycerol test was done on the third admission. Two hours after the administration of glycerol, the patient complained of rotatory vertigo with a downbeat vertical nystagmus. This nystagmus then changed its direction upward. Her left hearing loss was improved during the glycerol test. On the day after the glycerol test, a caloric test was done. The caloric response of the right ear was remarkably improved. Although she had not felt a hearing loss in the right ear, an overwritten audiogram showed a fluctuation of hearing in the right ear. The bilateral caloric responses fluctuated. From these findings, it appears that the function of the inner ear on both sides fluctuating. We speculate that the administration of glycerol elicited an asymmetry in the function of the inner ear on both sides and ocuured vertigo with vertical nystagmus because of the irritation of both ears.

Audiometry↗

[Vestibular neurectomy in the treatment of Meniere's disease].

INTRODUCTION: A brief history of vestibular neurectomy is given. This treatment was introduced in Denmark by us, based upon our large experience with translabyrinthine removal of vestibular schwannomas. MATERIAL: Includes all patients (43 operations in 42 patients) who had section of the vestibular nerve performed in the period from 1980 to 1996. Mean age was 51 years and the postoperative observation period varied from 2 to 15 years, mean 6.4 years. RESULTS: The vertigo was under control in 88% of the patients. Fourteen patients developed some imbalance after surgery caused by the abolished vestibular function in the ear involved. Thirty-nine patients indicated satisfaction with the operation, 92% retained their preoperative hearing. Only few and slight complications were seen, including two re-operations for CSF leaks and a slight transient facial nerve paresis. DISCUSSION AND CONCLUSIONS: The results are in accordance with those obtained by other authors, and retrosigmoid section of the vestibular nerves is an effective treatment of vertigo refractory to other treatment modalities. In order to reduce the patients' worries about undergoing an intracranial intervention it is important to inform the patients and patients' associations about the good results obtained by this treatment and in particular to inform about the very few complications. Due to the limited number of patients needing this treatment, and the need for surgical experience in order to maintain the favorable results, centralization of the treatment is mandatory.

Adult↗

Intratympanic gentamicin treatment in Meniere's disease: patients' experiences and outcomes.

OBJECTIVE: The aim of this study was to assess the experiences and outcomes of patients receiving intratympanic gentamicin treatment for Ménière's disease in Norfolk, UK. DESIGN: This study was based on a retrospective questionnaire survey and a review of patients' medical records. SETTING: Two district hospitals. PARTICIPANTS: All 29 patients treated between 1999 and 2001, with a minimum follow up of two years post-treatment, were included in the study. Twenty-three patients completed the questionnaires (79 per cent response rate). MAIN OUTCOME MEASURES: Glasgow benefit inventory (GBI) and vertigo symptom scale (VSS) scores, plus change in hearing thresholds. RESULTS: The mean GBI total score was +36, indicating substantial improvement in patients' overall quality of life following gentamicin treatment. The VSS scores demonstrated low levels of vertigo or unsteadiness in treated patients. Three patients suffered deterioration in their hearing thresholds following a single injection of gentamicin. However, 96 per cent of responders stated that they would be willing to have such treatment again, if necessary. CONCLUSION: Intratympanic gentamicin treatment ought to be offered to Ménière's patients suffering from disabling vertigo, with the proviso that they be made aware of the possibility of hearing deterioration.

Adult↗

The effects of transtympanic micropressure treatment in people with unilateral Meniere's disease.

OBJECTIVE: To evaluate the efficacy of a portable low-intensity alternating pressure generator, the Meniett device, in controlling the symptoms of Ménière's disease. DESIGN: A randomized, placebo-controlled, double-blind, multicenter clinical trial of 4 months' duration. SETTING: Four study sites: 3 academic medical centers and 1 private practice. PATIENTS: Sixty-seven people aged 33 to 71 years with established, active, unilateral cochleovestibular Ménière's disease randomly assigned to a treatment or control group. Five cases were excluded (2 dropouts, 3 protocol violations), leaving 62 evaluable cases. INTERVENTION: The Meniett device was self-administered 3 times daily. The placebo Meniett device was identical but exerted no pressure. All participants had a tympanostomy tube inserted in the affected ear. MAIN OUTCOME MEASURES: Participants rated vertigo and activity each day on a symptom report card. Hearing tests, electrocochleography, and questionnaires were completed at baseline, 2 months, and 4 months. RESULTS: The treatment group experienced significantly less severe vertigo, fewer days with definitive vertigo, and fewer days lost from work (sick days) during the follow-up period than did the control group. Hearing and electrocochleographic results did not differ between the groups. Outcomes did not differ by age, gender, laterality, or duration of symptoms. Outcomes were affected by vestibular loss and baseline level of vertigo. The tympanostomy tube had no short-term effect on vertigo symptoms. There were no complications from using the Meniett device. CONCLUSION: The Meniett device is a minimally invasive, safe, and efficacious intermediate treatment for people with substantial vertigo uncontrolled by medical therapy.

Adult↗

[Intratympanic gentamycin in association with human fibrin glue in the treatment of Meniere's disease: preliminary results].

The treatment of Menierè's disease (Md) with intratympanic gentamicin has rapidly become one of the most widespread alternatives to surgery in this disorder. Numerous studies, employing different protocols, have reported the use of this antibiotic in the treatment of disabling forms of Md, with success rates in the control of vestibular symptoms varying from 73 to 100%, associated with a rate of hearing complications varying from 0 to 75%. We have reported the results of a preliminary experience carried out in 10 patients affected by monolateral Md who were managed with ablation treatment effected with a mixture of gentamicin and human fibrin glue. Upon follow-up examination after one year, all of the patients presented a marked reduction in vestibular reflectivity on the side treated. The vertigo score was zero in all of the patients, showing that the vertigo symptoms were entirely under control. When patients were asked to rate their disability, vertigo was assessed as completely under control in 7 patients and substantially under control in the remaining 3. None of the patients presented any loss of hearing. On the basis of this experience, we propose a standardized protocol which, using an extremely low overall dose of gentamicin, enables elevated success rates to be obtained with the lowest possible number of injections, thus minimizing the risks to hearing. Intratympanic gentamicin associated with a fibrin carrier in Md appears to enable a standardized dose of the drug to be employed, resulting in a decided reduction in the number of administrations and in the overall dose of the drug applied. This makes it possible, with equal benefits in vertigo control, to significantly minimize any hearing loss.

Administration, Topical↗

Stress in hearing and balance in Meniere's disease.

Stress is an unavoidable every-day phenomenon. Physiological coping with stress depends on the appropriate release of stress hormones as well as their alleviation at the termination of the stress. Despite quite a body of research indicating that stress affects inner ear function, this concept has found little application in otolaryngology. Today's evidence clearly indicates that the inner ear is equipped to detect stress hormones and some of these hormones have been shown to affect the inner ear function. Major stress control pathways shown to affect the inner ear include several third order axes, the hypothalamus-pituitary-adrenal axis, the hypothalamus-pituitary-thyroid axis and the hypothalamus-pituitary-gonadal axis whose functioning are interactive and inter-dependent. Less well-studied are the second order hypothalamus-pituitary control axis and its interaction with other hormones. To explore these we carried out a retrospective study on a series of Ménière's patients who had undergone a neurotomy of the vestibular nerve in the dept of ORL at the Hopital Nord, Marseille. Ménière's patients were particularly appropriate for this study since stress has long been recognised as a factor associated with the triggering of the symptoms of this pathology. Patients with acoustic neuroma and facial spasm were taken as a control population. We investigated the level of a battery of stress hormones including prolactin beta-endorphin and growth hormone. The blood sample was taken on the morning before surgery. The most striking observation was the presence of hyperprolactinemia in 30% of the Ménière patients (more than 20 microg/l) with confirmation of prolactinoma in 6 patients. The level of beta-endorphin could also be elevated. Horner, K.C., Guieu, R., Magnan, J., Chays, A. and Cazal, Y. Neuropysychopharmacology, (2001) 26:135-138. These observations suggest that neuroendocrinological feedback pathways controlling stress can be disturbed in Ménière's patients and depression of hypothalamic dopaminergic inhibition of prolactin secretion might be implicated. A further study on non-operated Ménière's patients presenting hyperprolactinemia and on dopamine agonist treatment, is needed in order to assess the role of stress in Ménière's patients. Progress in this domain could open the door towards integration of the stress concept into clinical management of various inner ear disorders.

Ear, Inner↗

[Ablation therapy with gentamycin in the treatment of Meniere's disease].

Historically the therapy for untreatable Ménière's disease (Md) has been surgery: conservative (cochleosacculotomy and decompression or sacco-endolymphatic shunt) or radical (labyrinthectomy and vestibular neurectomy). A valid alternative to surgery is the use of ototoxic drugs such as aminoglycoside antibiotics based on the assumption that some of the drugs exert greater ototoxicity vs. the posterior labyrinth. The purpose of the present study was to verify a severe protocol for the intratympanic administration of gentamicin sulfate in the treatment of Md unresponsive to medical treatment. A total of 29 patients were recruited for the study, all suffering from monolateral Md with reduced or normal (i.e. not absent) vestibular reflectivity on the side involved. The protocol called for audiovestibular testing prior to the treatment cycle and then 7 days after the administration of each individual dose. The same treatment scheme was used in all patients: a weekly intratympanic injection of gentamicin, 16 mg/per dose, for a maximum of 2 or 3 treatments. Of these cases, 20 have been followed up for 2 or more years and these are described in the present study. The follow-up called for suspending treatment and then repeating the audiovestibular tests every six months. Equilibrium was fully controlled in 70% of the patients while control was substantial in 30%. Audiometry showed that the auditory threshold remained unchanged in 60% of the cases while it worsened in 20% and, surprisingly, improved in the remaining 20%. In two cases deafness arose after the second treatment. The vestibular tests showed an uncompensated areflexia on the treated side after the therapeutic cycle although, in all cases, this had been compensated by the time of observation at 24 months. Symptoms of deafness remained unchanged. In conclusion, with respect to other more invasive treatments, chemical labyrinthectomy is simpler to perform and has fewer side effects while producing analogous clinical results.

Adult↗

Intratympanic gentamicin in monolateral Meniere's disease: our experience.

The aim of this study was to verify the efficacy of a modified Odkvist titration protocol of intratympanic gentamicin application in the control of vertigo attacks and the effects on the auditory and vestibular function in a group of 71 patients affected by monolateral MD resistant to medical therapy. All the patients underwent an intratympanic administration of a 1-ml solution containing 26.6 mg of gentamicin sulfate. The treatment protocol provided one to three injections for a total amount of gentamicin varying from 26.6 to 80 mg. Five days after the first gentamicin administration, cochlear and vestibular function tests were performed. The worsening of the PTA greater than 15 dB, the appearance of clinical signs of vestibulotoxicity such as imbalance or persistent spontaneous nystagmus beating away from the injected ear or of a "curative vertigo" were the criteria taken into consideration to stop the treatment. In the absence of any sign, a second and third injection were performed. The presence of an unchanged frequency of the attacks at least 3 months after the previous cycle was the parameter considered to perform a second or third cycle. Seventeen (24%) patients were submitted to a second cycle of therapy and two (3%) to a third cycle. After a mean follow-up period of 20.3 months (range: 3 to 48) all 71 patients experienced good control of the vertigo attacks: grade A in 46 cases and grade B in 25 cases according to the AAO-HNS CoHE criteria. The pure tone average (PTA) hearing threshold (500-3,000 Hz) worsened in 19 patients, improved in 5 and was unchanged in 47. On the basis of the experience acquired during the treatment, we progressively decreased the number of injections from 3/cycle to a 1-2/cycle of therapy. Moreover, in the later phase of the study re-injections were administered 1 or 2 weeks after the previous application and avoided in the presence of signs of depression of the vestibular and/or cochlear function. A residual caloric excitability was found in 30% of the cases. Vertigo control doesn't seem to be linked to the achievement of vestibular inexcitability. The marker of successful gentamicin treatment at short-term is the appearance of signs of curative vertigo and/or vestibular imbalance, and at long-term the disappearance of vertigo attacks.

Adult↗